{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:53:05Z","timestamp":1791219185016,"version":"4.1.0"},"reference-count":23,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Adeno-associated viral (AAV) vectors (serotype 2) efficiently transduce skeletal muscle, and have been used as gene delivery vehicles for hemophilia B and for muscular dystrophies in experimental animals and humans. Recent reports suggest that AAV vectors based on serotypes 1, 5, and 7 transduce murine skeletal muscle much more efficiently than AAV-2, with reported increases in expression ranging from 2-fold to 1000-fold. We sought to determine whether this increased efficacy could be observed in species other than mice. In immunodeficient mice we saw 10- to 20-fold higher levels of human factor IX (hF.IX) expression at a range of doses, and in hemophilic dogs we observed approximately 50-fold higher levels of expression. The increase in transgene expression was due partly to higher gene copy number and a larger number of cells transduced at each injection site. In all immunocompetent animals injected with AAV-1, inhibitory antibodies to F.IX developed, but in immunocompetent mice treated with high doses of vector, inhibitory antibodies eventually disappeared. These studies emphasize that the increased efficacy of AAV-1 vectors carries a risk of inhibitor formation, and that further studies will be required to define doses and treatment regimens that result in tolerance rather than immunity to F.IX.<\/jats:p>","DOI":"10.1182\/blood-2003-05-1446","type":"journal-article","created":{"date-parts":[[2003,9,16]],"date-time":"2003-09-16T00:48:15Z","timestamp":1063673295000},"page":"85-92","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":137,"title":["Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1"],"prefix":"10.1182","volume":"103","author":[{"given":"Valder R.","family":"Arruda","sequence":"first","affiliation":[{"name":"From the Department of Pediatrics, University of Pennsylvania Medical Center and The Children's Hospital of Philadelphia, PA; the Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill; Avigen Inc, Alameda, CA; and the Howard Hughes Medical Institute, Philadelphia, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Schuettrumpf","sequence":"additional","affiliation":[{"name":"From the Department of Pediatrics, University of Pennsylvania Medical Center and The Children's Hospital of Philadelphia, PA; the Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill; Avigen Inc, Alameda, CA; and the Howard Hughes Medical Institute, Philadelphia, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland W.","family":"Herzog","sequence":"additional","affiliation":[{"name":"From the Department of Pediatrics, University of Pennsylvania Medical Center and The Children's Hospital of Philadelphia, PA; the Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill; Avigen Inc, Alameda, CA; and the Howard Hughes Medical Institute, Philadelphia, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy C.","family":"Nichols","sequence":"additional","affiliation":[{"name":"From the Department of Pediatrics, University of Pennsylvania Medical Center and The Children's Hospital of Philadelphia, PA; the Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill; Avigen Inc, Alameda, CA; and the Howard Hughes Medical Institute, Philadelphia, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Robinson","sequence":"additional","affiliation":[{"name":"From the Department of Pediatrics, University of Pennsylvania Medical Center and The Children's Hospital of Philadelphia, PA; the Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill; Avigen Inc, Alameda, CA; and the Howard Hughes Medical Institute, Philadelphia, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Lotfi","sequence":"additional","affiliation":[{"name":"From the Department of Pediatrics, University of Pennsylvania Medical Center and The Children's Hospital of Philadelphia, PA; the Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill; Avigen Inc, Alameda, CA; and the Howard Hughes Medical Institute, Philadelphia, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Mingozzi","sequence":"additional","affiliation":[{"name":"From the Department of Pediatrics, University of Pennsylvania Medical Center and The Children's Hospital of Philadelphia, PA; the Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill; Avigen Inc, Alameda, CA; and the Howard Hughes Medical Institute, Philadelphia, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Xiao","sequence":"additional","affiliation":[{"name":"From the Department of Pediatrics, University of Pennsylvania Medical Center and The Children's Hospital of Philadelphia, PA; the Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill; Avigen Inc, Alameda, CA; and the Howard Hughes Medical Institute, Philadelphia, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda B.","family":"Couto","sequence":"additional","affiliation":[{"name":"From the Department of Pediatrics, University of Pennsylvania Medical Center and The Children's Hospital of Philadelphia, PA; the Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill; Avigen Inc, Alameda, CA; and the Howard Hughes Medical Institute, Philadelphia, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A.","family":"High","sequence":"additional","affiliation":[{"name":"From the Department of Pediatrics, University of Pennsylvania Medical Center and The Children's Hospital of Philadelphia, PA; the Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill; Avigen Inc, Alameda, CA; and the Howard Hughes Medical Institute, Philadelphia, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021223014890600_REF1","doi-asserted-by":"crossref","unstructured":"Wagner JA, Moran ML, Messner AH, et al. A phase I\/II study of tgAAV-CF for the treatment of chronic sinusitis in patients with cystic fibrosis. Hum Gene Ther. 1998;9: 889-909.","DOI":"10.1089\/hum.1998.9.6-889"},{"key":"2020021223014890600_REF2","doi-asserted-by":"crossref","unstructured":"Manno CS, Chew AJ, Hutchison S, et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood. 2003;101: 2963-2972.","DOI":"10.1182\/blood-2002-10-3296"},{"key":"2020021223014890600_REF3","doi-asserted-by":"crossref","unstructured":"Stedman H, Wilson JM, Finke R, Kleckner AL, Mendell J. Phase I clinical trial utilizin gene therapy for limb girdle muscular dystrophy: alpha-, beta-, gamma-, or delta-sarcoglycan gene delivered with intramuscular instillations of adeno-associated vectors. Hum Gene Ther. 2000;11: 777-790.","DOI":"10.1089\/10430340050015671"},{"key":"2020021223014890600_REF4","doi-asserted-by":"crossref","unstructured":"Chao H, Liu Y, Rabinowitz J, Li C, Samulski RJ, Walsh CE. Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol Ther. 2000;2: 619-623.","DOI":"10.1006\/mthe.2000.0219"},{"key":"2020021223014890600_REF5","doi-asserted-by":"crossref","unstructured":"Duan D, Yan Z, Yue Y, Ding W, Engelhardt JF. Enhancement of muscle gene delivery with pseudotyped adeno-associated virus type 5 correlates with myoblast differentiation. J Virol. 2001;75: 7662-7671.","DOI":"10.1128\/JVI.75.16.7662-7671.2001"},{"key":"2020021223014890600_REF6","doi-asserted-by":"crossref","unstructured":"Xiao W, Chirmule N, Berta SC, McCullough B, Gao G, Wilson JM. Gene therapy vectors based on adeno-associated virus type 1. J Virol. 1999;73: 3994-4003.","DOI":"10.1128\/JVI.73.5.3994-4003.1999"},{"key":"2020021223014890600_REF7","doi-asserted-by":"crossref","unstructured":"Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A. 2002;99: 11854-11859.","DOI":"10.1073\/pnas.182412299"},{"key":"2020021223014890600_REF8","doi-asserted-by":"crossref","unstructured":"Rutledge EA, Halbert CL, Russell DW. Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J Virol. 1998;72: 309-319.","DOI":"10.1128\/JVI.72.1.309-319.1998"},{"key":"2020021223014890600_REF9","doi-asserted-by":"crossref","unstructured":"Evans JP, Brinkhous KM, Brayer GD, Reisner HM, High KA. Canine hemophilia B resulting from a point mutation with unusual consequences. Proc Natl Acad Sci U S A. 1989;86: 10095-10099.","DOI":"10.1073\/pnas.86.24.10095"},{"key":"2020021223014890600_REF10","doi-asserted-by":"crossref","unstructured":"Herzog R, Yang E, Couto L, et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adenoassociated viral vector. Nature Med. 1999;5: 56-63.","DOI":"10.1038\/4743"},{"key":"2020021223014890600_REF11","doi-asserted-by":"crossref","unstructured":"Herzog RW, Fields PA, Arruda VR, et al. Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy. Hum Gene Ther. 2002;13: 1281-1291.","DOI":"10.1089\/104303402760128513"},{"key":"2020021223014890600_REF12","doi-asserted-by":"crossref","unstructured":"Matsushita T. Adeno-associated virus vector can be efficiently produced without helper virus. Gene Therapy. 1998;5: 938-945.","DOI":"10.1038\/sj.gt.3300680"},{"key":"2020021223014890600_REF13","doi-asserted-by":"crossref","unstructured":"Herzog R, Hagstrom N, Kung S, et al. Stable gene transfer and expression of human FIX following intramuscular injection of recombinant AAV. Proc Natl Acad Sci U S A. 1997;94: 5804-5809.","DOI":"10.1073\/pnas.94.11.5804"},{"key":"2020021223014890600_REF14","doi-asserted-by":"crossref","unstructured":"Arruda VR, Hagstrom JN, Deitch J, et al. Post-translational modifications of recombinant myotube-synthesized human factor IX. Blood. 2001;97: 130-138.","DOI":"10.1182\/blood.V97.1.130"},{"key":"2020021223014890600_REF15","doi-asserted-by":"crossref","unstructured":"Evans JP, Watzke HH, Ware JL, Stafford DW, High KA. Molecular cloning of a cDNA encoding canine factor IX. Blood. 1989;74: 207-212.","DOI":"10.1182\/blood.V74.1.207.207"},{"key":"2020021223014890600_REF16","doi-asserted-by":"crossref","unstructured":"Herzog RW, Arruda VR, Fisher TH, Read MS, Nichols TC, High KA. Absence of circulating factor IX antigen in hemophilia B dogs of the UNC-Chapel Hill colony. Thromb Haemost. 2000;84: 352-354.","DOI":"10.1055\/s-0037-1614021"},{"key":"2020021223014890600_REF17","doi-asserted-by":"crossref","unstructured":"Snyder RO, Miao C, Meuse L, et al. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat Med. 1999;5: 64-70.","DOI":"10.1038\/4751"},{"key":"2020021223014890600_REF18","doi-asserted-by":"crossref","unstructured":"Fields PA, Arruda VR, Armstrong E, et al. Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9. Mol Ther. 2001;4: 201-210.","DOI":"10.1006\/mthe.2001.0441"},{"key":"2020021223014890600_REF19","doi-asserted-by":"crossref","unstructured":"Fields PA, Kowalczyk DW, Arruda VR, et al. Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX. Mol Ther. 2000;1: 225-235.","DOI":"10.1006\/mthe.2000.0032"},{"key":"2020021223014890600_REF20","doi-asserted-by":"crossref","unstructured":"Lin HF, Maeda N, Smithies O, Straight DL, Stafford DW. A coagulation factor IX-deficient mouse model for human hemophilia B. Blood. 1997;90: 3962-3966.","DOI":"10.1182\/blood.V90.10.3962"},{"key":"2020021223014890600_REF21","doi-asserted-by":"crossref","unstructured":"Herzog RW, Mount JD, Arruda VR, High KA, Lothrop CD Jr. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation. Mol Ther. 2001;4: 192-199.","DOI":"10.1006\/mthe.2001.0442"},{"key":"2020021223014890600_REF22","doi-asserted-by":"crossref","unstructured":"Pastore L, Morral N, Zhou H, et al. Use of liver-specific promoter reduces immune response to the transgene in adenoviral vectors. Hum Gene Therapy. 1999;10: 1773-1781.","DOI":"10.1089\/10430349950017455"},{"key":"2020021223014890600_REF23","doi-asserted-by":"crossref","unstructured":"Zinkernagel RM. Localization dose and time of antigens determine immune reactivity. Seminars in Immunology. 2000;12: 163-171.","DOI":"10.1006\/smim.2000.0253"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/103\/1\/85\/1694091\/zh800104000085.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/103\/1\/85\/1694091\/zh800104000085.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T04:02:00Z","timestamp":1581566520000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/103\/1\/85\/17587\/Safety-and-efficacy-of-factor-IX-gene-transfer-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2003-05-1446","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,1,1]]}}}